1.
A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. Indian J Case Reports [Internet]. 2022 Mar. 27 [cited 2024 Nov. 21];8(3):58-61. Available from: https://mansapublishers.com/index.php/ijcr/article/view/3317